RedHill’s Talicia Receives Patent from the USPTO for the Treatment of H. Pylori Infections
Shots:
- The USPTO has granted US Patent No. 11,878,011 to RedHill Biopharma’s Talicia, expected to protect it until May 2042, to eliminate Helicobacter pylori (H. pylori) irrespective of the Body Mass Index (BMI) of the patient. The drug is now eligible for 8yrs. of market exclusivity under QIDP designation
- The patent was issued based on collective data from two P-III trials demonstrating Talicia’s efficacy that remained unaffected by elevated BMI
- Talicia (oral) is a rifabutin-based therapy formulated by combining amoxicillin, rifabutin and omeprazole and indicated for treating adults with H. pylori infections
Ref: RedHill | Image: RedHill
Related News:- RedHill Biopharma’s Talicia Receives Approval in the United Arab Emirates for the Treatment of H. Pylori
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
